Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.

Stock Information for Skye Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.